Veristat and Cidara Therapeutics Collaborate with a Preferred Provider Agreement
Veristat to Assist Cidara with Its Trials for Novel Echinocandin Antifungal CD101
SOUTHBOROUGH, MA – January 12, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today a new partnership and Preferred Provider Agreement (PPA) with Cidara Therapeutics, a clinical stage biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections. Specific to the agreement, Veristat will offer Cidara clinical trial support with statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of materials for regulatory submissions. Veristat will support Cidara as its biometrics provider for the Phase 2 clinical trials of its antifungal agents, CD101 IV for the treatment of candidemia and CD101 Topical for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC.
“We look forward to collaborating with Veristat as we bring CD101 IV and CD101 Topical into Phase 2 trials this year,” said Dirk Thye, M.D., Chief Medical Officer at Cidara Therapeutics, “We trust that the Veristat team will continue to help us accelerate our antifungal programs through the development process.”
“Veristat is excited to be partnering with an anti-infectives innovator such as Cidara,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “The experience in providing strategic guidance and full-service support to anti-infective development programs has positioned Veristat to make a meaningful contribution to the speed, efficiency and effectiveness of Cidara’s development of this promising compound.”
Veristat is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring, project management and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit www.veristat.com.
Gillian Dellacioppa, Marketing Director
email@example.com or 508-306-6336